Around the world, the Servier Group’s 22,000 employees are committed to therapeutic progress in cardiology to serve patient needs.
Cardiovascular diseases are the leading cause of mortality in the world and are responsible for 31% of deaths every year. Committed for more than 60 years to the treatment of these pathologies, Servier has acquired recognized expertise and leadership in Cardiology.
More than 17 million patients worldwide are being treated every day with a Servier medicine for a condition affecting the heart or blood vessels.
SERVIER IN CARDIOLOGY:
largest player worldwide and 2nd in Europe
medicines available to health care professionals and patients
Servier continues to innovate in cardiology: by developing new products and services for and with patients.
Servier has been a major sponsor of the ESC for many years and will again be one of the leading pharmaceutical companies present at the 2020 congress, bringing together a variety of activities: portfolio offer, medical affairs, disease awareness campaigns as well as new technologies with a space dedicated to WeHealth. Many scientific symposiums will be organized by the Servier Group to share the latest medical data on hypertension, angina and heart failure.
The aim of Servier’s teams at virtual ESC congress: present the therapeutic solutions of the Group to healthcare professionals and provide them with a wide range of information on the products and services, especially adapted in the Covid-19 context.